Skip to main content

Table 3 Fasting metabolic abnormalities by ADT group (safety sample)

From: Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study

Metabolic measurement

Incidence of potentially clinically relevant fasting metabolic abnormalities, n (%)

Mean (SE) fasting metabolic parameters, mg/dL

Bupropion plus aripiprazole

SSRI/SNRI plus aripiprazole

Bupropion plus aripiprazole1

SSRI/SNRI plus aripiprazole2

   

Baseline

Change from baseline at Week 52

Baseline

Change from baseline at Week 52

Glucose

3/36 (8.3)

35/201 (17.4)

95.0 (2.4)

1.4 (1.9)

94.4 (1.3)

2.7 (1.5)

Total cholesterol

9/36 (25.0)

70/202 (34.7)

209.6 (6.3)

-0.9 (6.6)

214.2 (3.2)

-0.9 (2.6)

LDL cholesterol

3/35 (8.6)

48/202 (23.8)

121.6 (5.3)

0.5 (5.7)

125.1 (2.9)

-3.1 (2.5)

HDL cholesterol

1/36 (2.8)

6/202 (3.0)

55.0 (3.0)

0.3 (1.4)

56.4 (1.2)

-0.5 (0.7)

Triglycerides

      

Male

9/13 (69.2)

34/65 (52.3)

183.0 (36.6)

7.5 (13.7)

180.0 (13.9)

28.2 (19.9)

Female

15/23 (65.2)

100/137 (73.0)

157.5 (16.0)

-25.3 (8.9)

156.9 (9.7)

8.5 (7.1)

  1. ADT, antidepressant treatment; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.
  2. Number of patients with both baseline and endpoint laboratory assessments: 1n = 32 (male, n = 11; female, n = 21); 2n = 181 (male, n = 58; female, n = 123) for all parameters except fasting glucose, where n = 179.